OMedLive

Online Events

HER2 Positive Breast Cancer

Breast Cancer ASCO

Pediatric Neuroblastoma

Multiple Myeloma

Hemophilia

Invasive Fungal Infections

Speakers

HER2 Positive Breast Cancer

  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.

Breast Cancer ASCO

  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.

Pediatric Neuroblastoma

  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio received her graduate degree from the University of Pennsylvania’s School of Nursing. She has been a Nurse Practitioner at The Children’s Hospital of Philadelphia for the past 17 years. Over the past 9 years she has been part of the Neuroblastoma Developmental Therapeutics Team specializing in the care of children with relapsed and refractory Neuroblastoma.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.

Multiple Myeloma

  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.
  • Shaji Kumar, MD

    Shaji Kumar, MD

    Shaji Kumar, MD

    Professor of Medicine, Hematology

    Shaji Kumar, MD, is a consultant in the Division of Hematology and professor of medicine at the Mayo Clinic in Rochester, Minnesota. His research efforts are directed toward studying novel treatment approaches in myeloma through clinical trials. He is currently principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, and his laboratory has focused on the development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar earned his MD from the All India Institute of Medical Sciences in New Delhi, completed a residency and fellowship at the Mayo School of Graduate Medical Education, and was a research associate and Mayo Foundation Scholar in multiple myeloma at the Dana-Farber/Harvard Cancer Center.

Hemophilia

  • Regina B. Butler, RN

    Regina B. Butler, RN

    Regina B. Butler, RN

    Clinical Manager, Hematology

    Regina B. Butler, RN, is Hemophilia Clinical Manager at the Children’s Hospital of Philadelphia (CHOP) and Director of the Hemophilia Treatment Centers in Region III. In her role at CHOP, Ms Butler coordinates the care of over 450 children with bleeding disorders in collaboration with a large, multi-disciplinary team. She has served as a consultant to the Centers for Disease Control and Prevention (CDC) since 2000 to assist in the development of educational materials and curricula on bleeding disorders for health care providers, patients, and families. Ms Butler has had significant involvement in professional committees and organizations within the hemophilia community, including the National Hemophilia Foundation’s (NHF) Nursing Committee, where she served as a founding member and Chairperson, NHF’s Medical and Scientific Advisory Council, and Maternal and Child Health Bureau Executive Committee. She is the former U.S. representative to the World Federation of Hemophilia (WFH) Nursing Committee and served as a member of its Communications Committee. Ms Butler has published numerous papers on hemophilia, patient/family education, nursing education, and nursing perspectives on hemophilia care and HIV risk reduction. She has presented locally, nationally and internationally on a variety of topics in hemophilia care.
  • Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Director of Strategic Operations, Hemophilia and Thrombosis Center

    Brenda Riske, RN, MSN, MBA, MPA, is Regional Coordinator/Administrator, Mountain States Hemophilia Network, and Director, Strategic Planning, at the University of Colorado Hemophilia & Thrombosis Center. Over the past 30 years, Ms Riske has worked in the area of hemophilia as a clinician, administrator, and clinical research manager. She has been active in national organizations that include the National Hemophilia Foundation, the Centers for Disease Control and Prevention (CDC), and the Health Resources Services Administration (HRSA)/Maternal and Child Health Bureau. She chaired the provider curriculum development committee for the Blood Clot Disorder Association, and has served as member of the Hemophilia Utilization Group Study (HUGS) Steering Committee since 2008. Ms Riske is also a member of the Board of the Partners in Hemophilia Education, a national training program for clinical staff at hemophilia treatment centers, where she serves on the subcommittee developing a credentialing program for nurses in hemophilia treatment centers. She has published articles in numerous peer-reviewed publications, including the Journal of Medical Economics, Haemophilia, and Transfusion.

Invasive Fungal Infections

  • Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Deputy Head, Division of Internal Medicine

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).
  • George R. Thompson, MD

    George R. Thompson, MD

    George R. Thompson, MD

    Associate Professor of Medicine

    Dr. Thompson is Assistant Professor of Clinical Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics and host immunogenetics. His current research focuses on the host-pathogen interaction of humans and both Coccidioides spp. (the agent of “Valley Fever”), and Cryptococcus spp. Dr. Thompson has served on the IDSA Journal Club which is a committee comprised of 12 panelists who select key papers for review and compose a summary of important articles that is published in the internationally disseminated monthly IDSA News. Additionally, he is a member of the Coccidioidomycosis Study Group Planning Committee, and as Co-chair of the Mycoses Study Group - a committee responsible for the development of content and dissemination of materials to practitioners across the United States, planning of the mycology content at yearly meetings (IDSA and ICAAC), and the design of clinical trials.
  • Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Associate Professor, Departments of Pathology & Medicine/Infectious Diseases

    Dr. Nathan P. Wiederhold is Associate Professor of Pathology and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio, and Adjoint Associate Professor of Pharmacy, at the University of Texas at Austin College of Pharmacy. Dr. Wiederhold received his Pharm.D. from the University of Texas at Austin in 2000, followed by pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a two-year research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederhold then joined the faculty of the University of Texas at Austin and the University of Texas Health Science Center at San Antonio in 2004. He then became the director of the Fungus Testing Laboratory in 2013. Dr. Wiederhold’s clinical and research areas include medical mycology, antifungal susceptibility and resistance, and antifungal therapeutic drug monitoring. He has over 100 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
  • Thomas Patterson, MD

    Thomas Patterson, MD

    Thomas Patterson, MD

    Division Head and Division Chief, Infectious Diseases

    Dr. Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas and his Medical Doctor from the University of Texas Medical School at Houston, Texas. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut where he also served as an Assistant Professor of Medicine. Dr. Patterson currently is a Professor of Medicine and Chief, Division of Infectious Diseases at the University of Texas Health Science Center in San Antonio, Texas. He is also Director of the San Antonio Center for Medical Mycology. He has extensive experience in invasive fungal infections. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds. Dr. Patterson has published and lectured extensively on fungal infections. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases, a Fellow of the American College of Physicians, Past-President of the Texas Infectious Disease Society, and current President, Immunocompromised Host Society.

All Speakers

  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio received her graduate degree from the University of Pennsylvania’s School of Nursing. She has been a Nurse Practitioner at The Children’s Hospital of Philadelphia for the past 17 years. Over the past 9 years she has been part of the Neuroblastoma Developmental Therapeutics Team specializing in the care of children with relapsed and refractory Neuroblastoma.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.
  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.
  • Shaji Kumar, MD

    Shaji Kumar, MD

    Shaji Kumar, MD

    Professor of Medicine, Hematology

    Shaji Kumar, MD, is a consultant in the Division of Hematology and professor of medicine at the Mayo Clinic in Rochester, Minnesota. His research efforts are directed toward studying novel treatment approaches in myeloma through clinical trials. He is currently principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, and his laboratory has focused on the development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar earned his MD from the All India Institute of Medical Sciences in New Delhi, completed a residency and fellowship at the Mayo School of Graduate Medical Education, and was a research associate and Mayo Foundation Scholar in multiple myeloma at the Dana-Farber/Harvard Cancer Center.
  • Regina B. Butler, RN

    Regina B. Butler, RN

    Regina B. Butler, RN

    Clinical Manager, Hematology

    Regina B. Butler, RN, is Hemophilia Clinical Manager at the Children’s Hospital of Philadelphia (CHOP) and Director of the Hemophilia Treatment Centers in Region III. In her role at CHOP, Ms Butler coordinates the care of over 450 children with bleeding disorders in collaboration with a large, multi-disciplinary team. She has served as a consultant to the Centers for Disease Control and Prevention (CDC) since 2000 to assist in the development of educational materials and curricula on bleeding disorders for health care providers, patients, and families. Ms Butler has had significant involvement in professional committees and organizations within the hemophilia community, including the National Hemophilia Foundation’s (NHF) Nursing Committee, where she served as a founding member and Chairperson, NHF’s Medical and Scientific Advisory Council, and Maternal and Child Health Bureau Executive Committee. She is the former U.S. representative to the World Federation of Hemophilia (WFH) Nursing Committee and served as a member of its Communications Committee. Ms Butler has published numerous papers on hemophilia, patient/family education, nursing education, and nursing perspectives on hemophilia care and HIV risk reduction. She has presented locally, nationally and internationally on a variety of topics in hemophilia care.
  • Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Brenda Riske, RN, MSN, MBA, MPA

    Director of Strategic Operations, Hemophilia and Thrombosis Center

    Brenda Riske, RN, MSN, MBA, MPA, is Regional Coordinator/Administrator, Mountain States Hemophilia Network, and Director, Strategic Planning, at the University of Colorado Hemophilia & Thrombosis Center. Over the past 30 years, Ms Riske has worked in the area of hemophilia as a clinician, administrator, and clinical research manager. She has been active in national organizations that include the National Hemophilia Foundation, the Centers for Disease Control and Prevention (CDC), and the Health Resources Services Administration (HRSA)/Maternal and Child Health Bureau. She chaired the provider curriculum development committee for the Blood Clot Disorder Association, and has served as member of the Hemophilia Utilization Group Study (HUGS) Steering Committee since 2008. Ms Riske is also a member of the Board of the Partners in Hemophilia Education, a national training program for clinical staff at hemophilia treatment centers, where she serves on the subcommittee developing a credentialing program for nurses in hemophilia treatment centers. She has published articles in numerous peer-reviewed publications, including the Journal of Medical Economics, Haemophilia, and Transfusion.
  • Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

    Deputy Head, Division of Internal Medicine

    Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).
  • George R. Thompson, MD

    George R. Thompson, MD

    George R. Thompson, MD

    Associate Professor of Medicine

    Dr. Thompson is Assistant Professor of Clinical Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics and host immunogenetics. His current research focuses on the host-pathogen interaction of humans and both Coccidioides spp. (the agent of “Valley Fever”), and Cryptococcus spp. Dr. Thompson has served on the IDSA Journal Club which is a committee comprised of 12 panelists who select key papers for review and compose a summary of important articles that is published in the internationally disseminated monthly IDSA News. Additionally, he is a member of the Coccidioidomycosis Study Group Planning Committee, and as Co-chair of the Mycoses Study Group - a committee responsible for the development of content and dissemination of materials to practitioners across the United States, planning of the mycology content at yearly meetings (IDSA and ICAAC), and the design of clinical trials.
  • Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Nathan P. Wiederhold, PharmD, FCCP

    Associate Professor, Departments of Pathology & Medicine/Infectious Diseases

    Dr. Nathan P. Wiederhold is Associate Professor of Pathology and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio, and Adjoint Associate Professor of Pharmacy, at the University of Texas at Austin College of Pharmacy. Dr. Wiederhold received his Pharm.D. from the University of Texas at Austin in 2000, followed by pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a two-year research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederhold then joined the faculty of the University of Texas at Austin and the University of Texas Health Science Center at San Antonio in 2004. He then became the director of the Fungus Testing Laboratory in 2013. Dr. Wiederhold’s clinical and research areas include medical mycology, antifungal susceptibility and resistance, and antifungal therapeutic drug monitoring. He has over 100 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.
  • Thomas Patterson, MD

    Thomas Patterson, MD

    Thomas Patterson, MD

    Division Head and Division Chief, Infectious Diseases

    Dr. Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas and his Medical Doctor from the University of Texas Medical School at Houston, Texas. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut where he also served as an Assistant Professor of Medicine. Dr. Patterson currently is a Professor of Medicine and Chief, Division of Infectious Diseases at the University of Texas Health Science Center in San Antonio, Texas. He is also Director of the San Antonio Center for Medical Mycology. He has extensive experience in invasive fungal infections. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds. Dr. Patterson has published and lectured extensively on fungal infections. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases, a Fellow of the American College of Physicians, Past-President of the Texas Infectious Disease Society, and current President, Immunocompromised Host Society.

Partners

Academic

  • logo-einstein

Associations

Publishers